Quick Takeaways:
- Anivive received full FDA Center for Veterinary Medicine approval for Laverdia (verdinexor tablets), the first FDA-approved oral at-home treatment for canine lymphoma, replacing its 2021 conditional approval.
- Laverdia is the first product developed through Anivive’s AI-enabled AniviveSELECT and AniviveTRIAL platforms, with the latter contributing ~40% of pivotal trial enrollment. The therapy is commercially available nationwide through Dechra Veterinary Products.
- Anivive is pursuing regulatory approvals for Laverdia in Australia, Brazil, Canada, Europe, Japan, and the UK, while also evaluating verdinexor for additional canine and feline cancers and expanding its SearchLight DNA cancer sequencing platform.
Why It Matters?
Full FDA approval for Laverdia transforms it from a conditionally approved option into the first fully approved oral, at‑home standard therapy for canine lymphoma, which should significantly boost veterinarian confidence and utilization via Dechra’s national distribution network. At the same time, it validates Anivive’s AI-driven development model, and signals a broader industry shift toward software-enabled oncology pipelines, with planned filings in multiple global markets.
Source: PRnewswire
